Jack Thomas Peterson

Mr. Jack Thomas Peterson

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYan-Hong Cui
Yan-Hong Cui
JWJiangbo Wei
Jiangbo Wei
HFHao Fan
Hao Fan
WLWenlong Li
Wenlong Li
LZLijie Zhao
Lijie Zhao
YHYu-Ying He
Yu-Ying He
Here, we show that vitamin E succinate (VES) acts as a degrader for the m 6 A RNA demethylase fat mass and obesity-associated protein (FTO), thus suppressing tumor growth and resistance to immunotherapy. FTO is ubiquitinated by its E3 ligase DTX2, followed by UFD1 recruitment and subsequent degradation in the proteasome. VES binds to FTO and DTX2, leading to enhanced FTO–DTX2 interaction, FTO ubiquitination, and degradation in FTO-dependent tumor cells. VES suppressed tumor growth and enhanced antitumor immunity and response to immunotherapy in vivo in mouse models. Genetic FTO knockdown or VES treatment increased m 6 A methylation in the LIF (Leukemia Inhibitory Factor) gene and decreased LIF mRNA decay, and thus sensitized melanoma cells to T cell–mediated cytotoxicity. Taken together, our findings reveal the underlying molecular mechanism for FTO protein degradation and identify a dietary degrader for FTO that inhibits tumor growth and overcomes immunotherapy resistance.

26 March 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
CMConnor McCloskey
Connor McCloskey
ASAnoop Sunkara
Anoop Sunkara
SKSiddhartha Kalala
Siddhartha Kalala
JPJack Thomas Peterson
Jack Thomas Peterson
MSMichael O'Connor Sohn
Michael O'Connor Sohn
Albert T AnastasioAlbert T Anastasio
Albert T Anastasio
Atypical joint spaces, such as those encountered in complex segmental bone loss and large structural defects, remain challenging to manage with conventional implants within divisions across orthopedics, including arthroplasty, tumor reconstruction, trauma, and spine. Additive manufacturing advances have made patient-specific implants a possibility, and this promising solution has enabled the creation of implants with customized geometry and controlled surface porosity to enhance osseointegration, reduce rejection rates, optimize biomechanics, and promote longevity. Despite its potential, patient-specific implants are still eclipsed in use by conventional, “off-the-shelf” implants due to their lower cost, documented long-term durability, insurance coverage, and the strength of available clinical evidence supporting their use. This narrative review summarizes current materials and manufacturing approaches for additively manufactured metal porous implants, including imaging and design workflows, lattice and pore architecture, and how the printing process influences implant stiffness, fatigue strength, surface roughness, and porosity. We also discuss the experimental and preclinical data on mechanical performance, fatigue resistance, and osseointegration for new developments in the field. Emerging trends such as material innovation, streamlined digital planning-to-implant workflows, 4D printing and other advanced additive manufacturing concepts, and cost-reduction efforts are examined in the context of clinical practicality. In this review, the integration of engineering principles with early clinical outcomes will provide orthopedic surgeons with a realistic understanding of the benefits and limitations of the future utilization of additive manufacturing in clinical practice.

18 August 2026 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
JPJack Thomas Peterson
Jack Thomas Peterson
JGJenny Guo
Jenny Guo
APAmir Patel
Amir Patel
JHJessica Helon
Jessica Helon
AMAlyssa McDonald
Alyssa McDonald
AKAmy E. Krambeck
Amy E. Krambeck
Purpose: To evaluate the safety and efficacy of emergency holmium laser enucleation of the prostate (HoLEP) for the management of refractory hematuria in the acute inpatient setting. Methods: A retrospective review of patients who underwent emergency HoLEP in the inpatient setting between January 2021 and August 2024 was performed. All procedures were performed by a single surgeon. Clinical and operative variables including indication for surgery, intra-operative findings, operative time, enucleated prostate volume, hospital course, perioperative transfusion requirements, post-operative catheterization status, and complications were collected. Post-operative outcomes including voiding trial success and catheter status at follow-up were assessed. Descriptive statistics were used to summarize patient characteristics and perioperative outcomes. Results: A total of 24 emergency HoLEPs were performed: all for refractory hematuria and one additionally for prostate abscess. During the same admission, five patients had previously undergone cystoscopic fulguration and evacuation procedures. Eight patients had prior transurethral resections of the prostate, two photoselective vaporization procedures, and one prostate artery embolization. The median operative time was 102 min, and the median enucleated prostate volume was 156 g. Eighteen (75%) of the patients passed their voiding trial on post-operative day 1, and all were catheter-free at three-month follow-up. Ten patients required blood transfusions, including eight preoperatively and seven postoperatively. No patients required additional procedures. Conclusion: From our cohort, emergency HoLEP appears to be a safe and effective treatment for refractory hematuria. Patients demonstrated high rates of early catheter removal and catheter-free voiding at follow-up, with no patients requiring additional procedures.

18 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAnoop Sunkara
Anoop Sunkara
CMConnor McCloskey
Connor McCloskey
DDDavid Antonio Dias
David Antonio Dias
SKSiddhartha Kalala
Siddhartha Kalala
JPJack Thomas Peterson
Jack Thomas Peterson
Albert T AnastasioAlbert T Anastasio
Albert T Anastasio
Musculoskeletal disorders involving bone, cartilage, tendon, and joint tissues represent a leading cause of disability worldwide, and conventional surgical and graft-based interventions are limited by donor site morbidity, incomplete integration, and finite durability. Despite substantial preclinical progress, translation into reliable clinical benefit has remained inconsistent. This narrative review synthesizes recent advances in bioengineered approaches to bone and joint repair, emphasizing how materials design and regenerative strategy selection influence translational feasibility. Advances in scaffold-based systems highlight the role of material composition, architectural organization, and structure–function matching in supporting musculoskeletal regeneration. Regenerative platforms including stem cell therapies, extracellular matrix-derived constructs, and smart materials are evaluated for biological performance, manufacturability, and regulatory feasibility. Early translational and clinical studies demonstrate encouraging outcomes across selected musculoskeletal indications; however, variability in efficacy and adoption highlights persistent barriers to broader implementation. Key challenges include scalable manufacturing, cost and reimbursement uncertainty, and heterogeneity in clinical infrastructure, factors that may also influence access to advanced regenerative therapies. Future innovations should emphasize manufacturability and real-world evidence generation that align with practical clinical pathways.

Verified
Journal Article
Open access
PDF file
JPJack Thomas Peterson
Jack Thomas Peterson
JGJenny N. Guo
Jenny N. Guo
APAmir Shahreza Patel
Amir Shahreza Patel
NKNabila Khondakar
Nabila Khondakar
PXPerry Xu
Perry Xu
AKAmy Krambeck
Amy Krambeck
Background/Objectives: Obesity has been associated with the development and severity of benign prostatic hyperplasia (BPH), yet its influence on outcomes following definitive surgical management, like holmium laser enucleation of the prostate (HoLEP), remains unclear. Furthermore, gradation of body mass index (BMI) severity has yet to discern personalized outcome stratification. We evaluated BMI’s influence on perioperative, immediate, short-term follow-up, and patient-reported outcomes for HoLEP patients. Methods: We performed a retrospective review of a prospectively maintained database of patients undergoing HoLEP for BPH at a single institution between January 2021 and August 2025. Outcomes included operative characteristics, post-operative complications, and validated symptom score changes. Analyses treated BMI as both a continuous and categorical variable. Multivariable linear and logistic regression models adjusted for common colinear confounders. Results: Among 1445 patients, BMI was not associated with most immediate, three-month, or patient-reported outcomes. Surgical complications were low across all BMI categories, and post-operative reported outcomes indicating high success rate for HoLEP. Higher BMI correlated with a modest increase in enucleation time (β = 0.197; p = 0.0132), increased odds of dysuria (OR = 1.084; p < 0.001), and change in American Urological Association Symptom Score (β = 0.211; p = 0.0334). All other operative metrics, complication rates, continence outcomes, and symptom scores (17 other total) were independent of BMI. Conclusions: After adjustment for relevant confounders, BMI does not meaningfully predict surgical safety, functional recovery, or patient-reported benefit following HoLEP. BMI alone should not influence candidacy or risk stratification for HoLEP in patients with BPH, instead favoring personalized, risk-stratified approaches.

31 October 2026 in Annals of Neurology
Verified
Journal Article
Open access
JPJack Thomas Peterson
Jack Thomas Peterson
CXClarissa Xia
Clarissa Xia
GNGovind Nair
Govind Nair
JSJoseph Snow
Joseph Snow
JSJulia Stone
Julia Stone
DPDarshan Pandya
Darshan Pandya
Objective: Quantify cytokines in cerebrospinal fluid (CSF) of virologically suppressed people with HIV (PWH) and people without HIV (PWoH) and correlate these with neuroimaging, neuropsychometric (NP), and neurodegenerative measurements. Methods: CSF samples were collected from virologically suppressed PWH and demographically matched PWoH under a natural history protocol. Participants underwent annual lumbar puncture, magnetic resonance imaging (MRI) brain scans, and NP testing at the National Institutes of Health (NIH). Using a magnetic bead assay, concentrations of 30 cytokines were measured in 136 PWH and 30 PWoH CSF samples, from 82 PWH and 25 unique PWoH participants. Results: Thirteen cytokines – IP‐10/CXCL10, G‐CSF, GM‐CSF, IL‐7, IL‐1ra, IL‐1α, MIP‐1β/CCL4, IL‐15, TNF‐α, IFN‐α2, IL‐10, IL‐8/CXCL8, and IL‐β – were significantly higher ( p < 0.05) in the CSF of PWH compared to PWoH. Five others were elevated, and one decreased, in PWH ( p = 0.05–0.10). Seven cytokines (EGF, IL‐15, IL‐6, IP‐10/CXCL10, MCP‐1/CCL2, MIP‐1α/CCL3, and TNF‐α) positively correlated with white matter lesion burden and 4 (eotaxin/CCL11, G‐CSF, GM‐CSF, and IL‐1ra) with white matter volume in PWH. Significant positive correlations were seen between cytokines, including IP‐10/CXCL10, MIP‐1α/CCL3, MIP‐1β/CCL4, IL‐15, IL‐6, and TNF‐α, and NP scores. IL‐10, IL‐15, IL‐8/CXCL8, IP‐10/CXCL10, MCP‐1/CCL2, MIP‐1α/CCL3, and VEGF positively correlated with CSF total tau and neurofilament light levels. Principal component analysis revealed discrete subsets of PWH. Demographics and comorbidities did not significantly impact differences between PWH and PWoH. Interpretation: Elevated expression of several cytokines in the CSF of virologically suppressed PWH indicates persistent immune activity and supports the existence of a central nervous system (CNS) reservoir. Numerous cytokines showed favorable associations with NP data, including “proinflammatory” cytokines such as IL‐6 and TNF‐α and several chemotactic cytokines, whereas some “anti‐inflammatory” cytokines such as IL‐10 correlated positively with unfavorable neurodegenerative markers. Our findings suggest that cytokine functions in the CNS of PWH vary from the periphery, are pleiotropic and potentially protective, and evolve over time. ANN NEUROL 2026